Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.38 |
| ▸ | CCNK | O75909 | 7/20 | 0.35 |
| ▸ | CDK12 | Q9NYV4 | 7/20 | 0.35 |
| ▸ | MTNR1A | P48039 | 5/20 | 0.34 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.32 |
| ▸ | DHFR | P00374 | 2/20 | 0.31 |
| ▸ | KCNA6 | P17658 | 1/20 | 0.31 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.31 |
| ▸ | KCNA4 | P22459 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29774308 | 0.83 | STK17B (0.45) | KMT2AMEN1 | |
| SCHEMBL20840000 | 0.80 | CCNK (0.44) | DAOCCNKCDK12DHFR | |
| SCHEMBL20839763 | 0.77 | MTNR1A (0.41) | MTNR1AMTNR1BKMT2AMEN1 | |
| SCHEMBL20839836 | 0.74 | CCNK (0.40) | DAOCCNKCDK12 | |
| SCHEMBL20840008 | 0.74 | CCNK (0.71) | CCNKCDK12 | |
| SCHEMBL13695024 | 0.70 | DAO (0.45) | DAOCCNKCDK12 | |
| SCHEMBL20839652 | 0.68 | CCNK (0.69) | CCNKCDK12 | |
| SCHEMBL16540928 | 0.67 | GLA (0.40) | KMT2AMEN1 | |
| SCHEMBL20839907 | 0.67 | CCNK (0.49) | CCNKCDK12 | |
| SCHEMBL26912587 | 0.64 | MTNR1A (0.44) | MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3684776-B1 | HETEROCYCLYL SUBSTITUTED PYRROLOPYRIDINES THAT ARE INHIBITORS OF THE CDK12 KINASE | UNIV NOTTINGHAM (GB) | 2023-11-01 | — | — | EP | disclosed |
| US-20200247824-A1 | HETEROCYCLYL SUBSTITUTED PYRROLOPYRIDINES THAT ARE INHIBITORS OF THE CDK12 KINASE | THE UNIVERSITY OF NOTTINGHAM (GB) | 2020-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200247824-A1 | HETEROCYCLYL SUBSTITUTED PYRROLOPYRIDINES THAT ARE INHIBITORS OF THE CDK12 KINASE | CDK1, CDK11A, CDK12 | DAO 2524/4885CCNK 18/4885CDK12 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.